Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

NCT01206049 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Panitumumab
DRUG: Bevacizumab

Sponsor

Vejle Hospital